BGB-16673
BGB-16673-104
Phase 2 small_molecule active
Quick answer
BGB-16673 for B-cell Malignancy is a Phase 2 program (small_molecule) at BeOne Medicines with 3 ClinicalTrials.gov record(s).
Program details
- Company
- BeOne Medicines
- Indication
- B-cell Malignancy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active